| 1.33 -0.03 (-2.21%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.84 | 1-year : | 2.11 |
| Resists | First : | 1.57 | Second : | 1.8 |
| Pivot price | 1.46  |
|||
| Supports | First : | 1.2 | Second : | 0.99 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.48 |
| MA(100) : | 1.48  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 17.1 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 19.51 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JUNS ] has closed above bottom band by 25.0%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.37 | 1.37 - 1.38 |
| Low: | 1.29 - 1.3 | 1.3 - 1.3 |
| Close: | 1.31 - 1.33 | 1.33 - 1.34 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Thu, 06 Nov 2025
Jupiter Neurosciences Expands Brain Health Focus with Consumer Supplement Line Nugevia - citybuzz -
Wed, 05 Nov 2025
Jupiter Neurosciences (NASDAQ: JUNS) wins FDA IND for Phase 2a Parkinson’s trial - Stock Titan
Wed, 05 Nov 2025
Jupiter Neurosciences Receives FDA Clearance of IND - GlobeNewswire
Tue, 28 Oct 2025
Jupiter Neurosciences Secures $20M Equity Purchase Agreement - The Globe and Mail
Mon, 27 Oct 2025
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - Yahoo Finance
Tue, 26 Aug 2025
Jupiter Neurosciences Launches Nugevia™ Website and Opens - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 54.6 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 140 (K) |
| Shares Short P.Month | 177 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -175.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.05 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -7.39 |
| PEG Ratio | 0 |
| Price to Book value | 33.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|